Contemporary Therapeutic Strategies for Solid Tumors: 2nd Edition

Dear Colleagues,

Solid tumors remain the leading cause of cancer-related mortality worldwide, and few areas of modern medicine are changing as quickly as their treatment. Targeted agents, immune checkpoint inhibitors, antibody–drug conjugates and, increasingly, cellular therapies have redefined what is achievable in nasopharyngeal, breast, lung, gastric, colorectal and hepatocellular carcinoma. Each advance, however, raises new questions: how should agents be sequenced, which patients truly benefit, how can resistance be anticipated and overcome, and how well do the outcomes of randomized trials translate into routine practice, particularly in older adults and in patients with substantial comorbidity?

This is the second volume of the Special Issue ‘Contemporary Therapeutic Strategies for Solid Tumors’ (https://www.mdpi.com/journal/life/special_issues/QFWZ9A1MVQ). The first volume attracted a wide readership and published work ranging from nationwide real-world cohort studies and target trial emulations to comprehensive therapeutic reviews. Building on that response, we are pleased to invite you to contribute to this second volume.

This Special Issue aims to bring together rigorous clinical and translational work that connects therapeutic innovation to measurable survival outcomes in solid tumors, in keeping with the scope of the Medical Research section of Life.

In this Special Issue, original research articles, systematic reviews, meta-analyses, and comprehensive reviews are welcome. Research areas may include (but are not limited to) the following:

• Targeted therapy, immunotherapy and antibody–drug conjugates in solid tumors;
• Emerging cellular therapies and other novel therapeutics;
• Biomarker-guided treatment selection and precision oncology;
• Optimal sequencing and combination treatment regimens;
• Real-world evidence, comparative effectiveness research and target trial emulation;
• Survival analysis and the identification of prognostic factors;
• Mechanisms of treatment resistance and strategies to overcome it;
• Management of older adults and patients with significant comorbidity;
• Treatment-related toxicity and supportive care.

We look forward to receiving your contributions

Dr. Chohao Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.